Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma

Background: The prognosis of recurrent or progressive medulloblastoma (MB) is still poor. This study was designed to investigate the potential therapeutic benefit of combination therapy with temozolomide (TMZ) and oral etoposide (VP-16) in children with progressive or relapsed MB. Given the oral administration of both drugs the regimen was administered outpatient. Methods: A phase I trial was conducted to establish the maximum tolerated dose (MTD) of TMZ and oral VP-16. This orally administered combination was investigated by classical 3+3 design. Cohorts of patients were enrolled at four different levels: (1) TMZ 120mg/m2 on days 1–5 and VP-16 50mg/m2 on days 1–8; (2) TMZ 150mg/m2 on days 1–5 and VP-16 50mg/m2 on days 1–8; (3) TMZ 150mg/m2 on days 1–5 and VP-16 50mg/m2 on days 1–10; (4) TMZ 150mg/m2 on days 1–5 and VP-16 50mg/m2 on days 1–12. Therapy was administered in 28-d courses. A total of 66 courses were administered to 14 patients with a median age of 5.7years. Results: None of the 3 patients at dose levels 1 and 2 had dose-limiting toxicity (DLT). Of the 6 patients at dose level 3, 1 patient had DLT. At dose level 4, grade 4 thrombocytopaenia and neutropaenia were observed in the first 2 patients enrolled. Therefore, the MTD was established at dose level 3. Conclusion: The recommended phase II dose in children is TMZ 150mg/m2 on days 1–5 and VP-16 50mg/m2 on days 1–10 every 28d. The combination was well tolerated and demonstrated antitumour activity. [Copyright &y& Elsevier]